Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2005
10/19/2005CN1683317A Ester compound of thymol and/or carvacrol, preparing method and its medicinal active composition
10/19/2005CN1683015A Polyvidone-phospholipid-cholate ternary composition used for difficult soluble medicine carrier
10/19/2005CN1683013A Oral administration gastric slow release preparation for treating chronic gastritis, peptic ulcer and intestinal infection
10/19/2005CN1223675C Anti tumor immunological active cell- DCIC cell, its preparing method and applications
10/19/2005CN1223608C Caspase-8 interacting proteins
10/19/2005CN1223340C Electrospun pharmaceutical compositions
10/18/2005US6956110 Genes involved in the molecular paths of tumor suppression and/or resistance to viruses
10/18/2005US6956060 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
10/18/2005US6956054 Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel
10/18/2005US6956051 amphiphilic drug-oligomer conjugates comprising a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled to a hydrophilic moiety; therapeutic agents coupled to amphiphilic oligomers
10/18/2005US6956045 Anticancer agents; antiallergens; immunology diseases; antiinflamamtory agents
10/18/2005US6956041 Protein kinase inhibitors
10/18/2005US6956026 Use of exendins for the reduction of food intake
10/18/2005US6956023 Materials and methods for providing nutrition to neonates
10/18/2005US6955815 Combinations for the treatment of inflammatory disorders
10/18/2005US6955814 protecting and/or preserving organs, in particular the heart during open-heart surgery, cardiovascular diagnosis or therapeutic intervention by administering potassium channel opener or agonist and adenosine receptor agonist and local anesthetic
10/18/2005US6955813 Therapy for injured muscles
10/18/2005US6955625 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/18/2005CA2152507C Novel combination of benzoquinazoline antifolates and protecting agents
10/18/2005CA2132544C Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
10/13/2005WO2005095621A1 Method of regulating gene introduction with use of artificial magnetic material and system therefor
10/13/2005WO2005095613A1 Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
10/13/2005WO2005095612A1 Gene encoding guanine nucleotide exchange factor and gene product thereof
10/13/2005WO2005095604A1 Rf rp transgenic animal
10/13/2005WO2005095587A1 Process for producing somatic stem cell differentiated from embryonic stem cell and use of the same
10/13/2005WO2005095373A1 Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
10/13/2005WO2005095372A1 Naphthalene derivative, medicinal composition containing the same, and medicinal use thereof
10/13/2005WO2005095356A1 Agent for generating heat or singlet oxygen and composition for cancer treatment each comprising organic peroxide or chemiluminescent compound
10/13/2005WO2005094918A1 Solid pharmaceutical preparation for dialysis
10/13/2005WO2005094892A1 Nutritional product
10/13/2005WO2005094890A1 Composition for increasing body height
10/13/2005WO2005094889A1 Remedy or preventive for arthritis
10/13/2005WO2005094888A1 Damaged tissue therapeutic agent and therapeutic method
10/13/2005WO2005094887A1 sFRP EXPRESSION POTENTIATING AGENT
10/13/2005WO2005094886A1 Methods of inducing differentiation of regulatory t-cells and proliferating the same with gpi anchor protein agonist and medicinal composition therefor
10/13/2005WO2005094885A1 Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain
10/13/2005WO2005094878A1 Composition having antitumor effect
10/13/2005WO2005094862A1 Compositions and method for alleviating inflammation and oxidative stress in a mammal
10/13/2005WO2005094854A1 Modified nutraceutical composition
10/13/2005WO2005094843A1 Rapidly disintegrating taste-masked tablet
10/13/2005WO2005094821A1 A medical composition for increasing the medicine safety
10/13/2005WO2005094809A1 A composition containing a complex comprising a metal ion and a carboxylate ligand having anti-inflammatory activity
10/13/2005WO2005094798A2 Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
10/13/2005WO2005094797A2 Use of ampa-receptor antagonists for treating dementia
10/13/2005WO2005094789A1 S/o type pharmaceutical preparation and process for producing the same
10/13/2005WO2005094553A2 Compositions for promoting bone growth and methods thereof
10/13/2005WO2005094384A2 Methods and compositions for treatment of ion imbalances
10/13/2005WO2005094376A2 Synergistic methods and compositions for treating cancer
10/13/2005WO2005094305A2 Combination therapy for weight management
10/13/2005WO2005094234A2 Dietary supplement for treating digestive system disorders
10/13/2005WO2005094218A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
10/13/2005WO2005082415A3 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
10/13/2005WO2005079766A3 Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
10/13/2005WO2005072113A3 Compositions and methods of treatment for inflammatory diseases
10/13/2005WO2005068468A3 Heterocyclic protein kinase inhibitors and uses thereof
10/13/2005WO2005046689A3 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
10/13/2005WO2005039493A3 Herbal composition for weight control
10/13/2005WO2005032387A3 Apparatus and method for administering a therapeutic agent
10/13/2005WO2005009336A3 Antibacterial methods and compositions
10/13/2005WO2004096118A3 Composition for improving cognition and memory
10/13/2005WO2004078113A3 Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
10/13/2005WO2002014467A9 Cng2b: a putative human cyclic nucleotide-gated ion channel
10/13/2005US20050229260 Compound screens relating to insulin deficiency or insulin resistance
10/13/2005US20050228184 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228053 Atamestane and toremifene dosage forms and kits for use treating breast cancer
10/13/2005US20050228044 benzodihydrofurans; high activity at PPAR alpha receptor; no activity at PPAR gamma and PPAR delta receptors; atherosclerosis, obesity, and vascular restenosis; 5-{3-[2-Chloro-4-(2,2,2-trifluoro-ethoxy)-phenoxy]-propoxy}-2-methyl-2,3-dihydro-benzofuran-2-carboxylic acid; no 1,3-thiazolidinedione moiety
10/13/2005US20050228033 Voltage-gated sodium channel (VGSC) and prostate voltage sodium channel (PVSC) inhibitors for treating diseases characterized by overabundant or hyperactive VGSC/PVSC's; phenytoin derivatives; use as sodium channel blockers, anti-cancer agents; can be used to limit or prevent PSA growth and metastasis
10/13/2005US20050228018 Chemical compounds
10/13/2005US20050228003 Mitotic kinesin inhibitors
10/13/2005US20050228001 Methods and compositions for treating platelet-related disorders
10/13/2005US20050227998 Compositions and methods of decreasing nicotine withdrawal
10/13/2005US20050227997 Selective inhibition of aggrecanase in osteoarthritis treatment
10/13/2005US20050227988 compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety
10/13/2005US20050227984 Drugs for improving the prognosis of brain injury and a method of screening the same
10/13/2005US20050227979 E.g., 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidine and 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane; these compounds modulate the activity of the histamine receptor, specifically the H3 receptor, without the inherent problems associated with the presence of an imidazolyl moiety
10/13/2005US20050227972 treating disorders of the cardiovascular system; adenosine receptor agonists/antagonists
10/13/2005US20050227967 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
10/13/2005US20050227929 parecoxib sodium and antineoplastic agent chosen from list of 150 compounds, vaccines, and biodrugs such as polyglutamic acid-paclitaxel
10/13/2005US20050227923 Stimulation of bone growth with thrombin peptide derivatives
10/13/2005US20050227287 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPSc
10/13/2005US20050227282 Human extracellular matrix-1
10/13/2005US20050227280 Proteases
10/13/2005US20050227277 Apoptosis proteins
10/13/2005US20050227249 Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
10/13/2005US20050227245 Reagents and methods for identifying and modulating expression of genes regulated by retinoids
10/13/2005US20050226949 Medical composition for managing hormone balance
10/13/2005US20050226942 A combination of Bacopa monniera extract, milk thistle extract, ashwagandha powder, green tea extract, and turmeric extract increases the enzyme activity level of superoxide dismutase and catalase and decreases the plasma concentration level of thiobarbituric acid reactive chemical species
10/13/2005US20050226940 Antitumour compositions containing taxane derivatives
10/13/2005US20050226931 Stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent; wound treatment
10/13/2005US20050226928 Synergistic mixture; hypoglycemic agents; sustained release; bioavailability; metformin with thiazolidinedione compound
10/13/2005US20050226920 Method of decreasing nicotine withdrawal symptoms during smoking cessation.
10/13/2005US20050226916 Hemostatic polymer useful for RAPID blood coagulation and hemostasis
10/13/2005US20050226907 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
10/13/2005US20050226906 Nutrient system for individualized responsive dosing regimens
10/13/2005US20050226903 Water-dispersible or water-soluble poloxamers provides a drug forms with good fracture strength, flexibility, and dimensional stability; counteract triglycerides brittleness; use of a medical stick for medical administration in body cavities and/or wound cavities; veterinary medicine
10/13/2005US20050226897 Method of protecting against coccidiosis
10/13/2005US20050226885 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
10/13/2005US20050226884 Using monoclonal antibody as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders; immunotherapy
10/13/2005US20050226875 Uses of anti-CTLA-4 antibodies
1 ... 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 ... 1151